Related Experiment Video
Updated: Aug 6, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
The coagulation system as a target for experimental therapy of human gliomas
1Section of Hematology/Oncology, DartmouthHitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03257, USA. James.T.Loynes@Hitchcock.org
Abstract:
The purpose of this paper is to review the rationale for the development of coagulation-reactive drugs for the experimental therapy of gliomas. Numerous reactants familiar to students of blood coagulation have been shown to contribute to neoplastic proliferation, invasion and metastasis. Recently, considerable progress has been made in demonstrating the ability of drugs capable of inhibiting these reactants to alter cancer progression. Biological features of gliomas within the realm of blood coagulation suggest that clinical trials of such drugs warrant consideration. This approach offers the prospect of a novel treatment for this devastating tumour type that does not share the toxicities of conventional cancer therapies.
Insights
This review explores using blood coagulation drugs to treat gliomas, a type of brain tumor. Targeting coagulation pathways may offer a novel, less toxic therapy for glioma progression.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Blood coagulation pathways play a role in cancer progression, including neoplastic proliferation, invasion, and metastasis.
- Gliomas exhibit biological features linked to blood coagulation processes.
- Conventional cancer therapies for gliomas often have significant toxicities.
Purpose of the Study:
- To review the rationale for developing coagulation-reactive drugs for experimental glioma therapy.
- To highlight the potential of targeting blood coagulation in novel cancer treatments.
- To suggest consideration of clinical trials for these drugs in glioma patients.
Main Methods:
- Literature review of studies on blood coagulation reactants in cancer.
- Analysis of biological links between gliomas and coagulation.
- Evaluation of preclinical data on drugs inhibiting coagulation pathways in cancer models.
Main Results:
- Numerous blood coagulation reactants are implicated in neoplastic progression.
- Drugs inhibiting these reactants have shown promise in altering cancer progression.
- The biological characteristics of gliomas suggest potential efficacy of coagulation-targeting drugs.
Conclusions:
- Coagulation-reactive drugs represent a promising novel therapeutic strategy for gliomas.
- Targeting blood coagulation offers a potential treatment modality with reduced toxicity compared to conventional therapies.
- Clinical trials of coagulation-inhibiting drugs for glioma warrant consideration.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026